Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following table presents selected financial information with respect to the Company's single operating segment for the years ended:

	Year Ended December 31,
	2024		2023
Collaboration revenue	$	210,782	$	129,013
Less:
Research and development expenses
Direct research and development expenses
ENTR-601-44	13,109		10,043
ENTR-601-45	8,584		9,782
ENTR-601-50	10,851		3,016
ENTR-601-51	1,345		1,531
Collaboration services	12,074		11,970
Other preclinical and discovery	7,926		6,712
Unallocated research and development expenses
Personnel related (including stock-based compensation)	41,762		31,250
Facility related and other	29,655		25,580
Total research and development expenses	125,306		99,884
General and administrative expenses	38,465		32,291
Interest and other income	19,474		15,218
Provision for income taxes	(859)		(18,741)
Net income (loss)	$	65,626	$	(6,685)